[
    {
        "question": "How many patients have Grade 0 gliomas in the dataset? Express the answer as an integer.",
        "ground_truth": "487",
        "derivation": "_.countBy(data, 'Grade')",
        "type": "Information Retrieval",
        "subtype": "Direct Value Retrieval",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "487 patients have Grade 0 gliomas in the dataset.",
        "score": 1
    },
    {
        "question": "What is the count of patients with concurrent IDH1 and TP53 mutations (both values = 1)? Express the answer as an integer.",
        "ground_truth": "238",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.TP53 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "238",
        "score": 1
    },
    {
        "question": "Which mutation appears most frequently in the dataset? Report the mutation name and count in the format: 'MUTATION_NAME: COUNT'.",
        "ground_truth": "IDH1: 404",
        "derivation": "Object.entries(mutationCounts).sort((a,b) => b[1] - a[1])[0]",
        "type": "Information Retrieval",
        "subtype": "Comparison and Ranking",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1: 404",
        "score": 1
    },
    {
        "question": "Calculate the mean age at diagnosis for each glioma grade. Round to 2 decimal places and express as 'Grade X: YY.ZZ'.",
        "ground_truth": "Grade 0: 43.87, Grade 1: 60.70",
        "derivation": "_.groupBy(data, 'Grade').map(group => calculateMean(group.map(p => p.Age_at_diagnosis)))",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Grade 0: 43.87\nGrade 1: 60.70\n\nThe analysis shows that patients with Grade 0 gliomas were diagnosed at a mean age of 43.87 years, while those with Grade 1 gliomas were diagnosed at a mean age of 60.70 years.",
        "score": 1
    },
    {
        "question": "What percentage of Grade 1 glioma patients have EGFR mutations? Round to 1 decimal place and include the raw counts in parentheses.",
        "ground_truth": "31.8% (112/352)",
        "derivation": "data.filter(row => row.Grade === 4 && row.EGFR === 1).length / data.filter(row => row.Grade === 4).length",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "23.0% (81/352) of Grade 1 glioma patients have EGFR mutations.",
        "score": 0
    },
    {
        "question": "Calculate the mean and standard deviation of Age_at_diagnosis. Round to 2 decimal places and express as 'Mean: XX.XX, SD: YY.YY'.",
        "ground_truth": "Mean: 50.94, SD: 15.69",
        "derivation": "const ages = data.map(row => row.Age_at_diagnosis).filter(age => age != null); calculateMean(ages); standardDeviation(ages)",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Mean: 50.94, SD: 15.70",
        "score": 1
    },
    {
        "question": "How many patients have both IDH1 and IDH2 mutations (both values = 1)? Express the answer as an integer.",
        "ground_truth": "0",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.IDH2 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "0",
        "score": 1
    },
    {
        "question": "Calculate the EGFR mutation rate for each glioma grade. Round to 2 decimal places and express as percentages in the format 'Grade X: YY.ZZ%'.",
        "ground_truth": "Grade 0: 6.37%, Grade 1: 23.01%",
        "derivation": "const egfrByGrade = _.groupBy(data, 'Grade'); Object.entries(egfrByGrade).map(([grade, patients]) => ({grade, egfrRate: patients.filter(p => p.EGFR === 1).length / patients.length}))",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Grade 0: 6.37%\nGrade 1: 23.01%\n\nThis shows that EGFR mutations are more common in Grade 1 gliomas (23.01%) compared to Grade 0 gliomas (6.37%), with the difference being quite substantial - nearly four times higher in Grade 1 tumors.",
        "score": 1
    },
    {
        "question": "Provide a population summary in the format: 'Total: N; Grade distribution: X/Y; Gender by grade: M0/F0, M1/F1; Most common mutation: NAME (COUNT)'.",
        "ground_truth": "Total: 839; Grade distribution: 487/352; Gender by grade: 271/216, 217/135; Most common mutation: IDH1 (404)",
        "derivation": "Multiple analyses combined",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Total: 839; Grade distribution: 487/352; Gender by grade: 271M/216F, 217M/135F; Most common mutation: IDH1 (404)",
        "score": 1
    },
    {
        "question": "Calculate the mean age and 95% CI for patients with IDH1 mutations. Round to 2 decimal places and express as 'Mean: XX.XX, CI: [YY.YY, ZZ.ZZ]'.",
        "ground_truth": "Mean: 41.67, CI: [40.48, 42.87]",
        "derivation": "confidenceInterval(data.filter(row => row.IDH1 === 1).map(row => row.Age_at_diagnosis))",
        "type": "Statistics",
        "subtype": "Confidence Intervals",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Mean: 41.67, CI: [40.48, 42.87]\n\nThis means that patients with IDH1 mutations have a mean age of 41.67 years, and we can be 95% confident that the true population mean falls between 40.48 and 42.87 years.",
        "score": 1
    },
    {
        "question": "Calculate the frequency of IDH1, TP53, and ATRX mutations for age groups: <30, 30-45, 45-60, and >60. Express as percentages rounded to 1 decimal place in the format 'Age GROUP: IDH1 (XX.X%), TP53 (YY.Y%), ATRX (ZZ.Z%)'.",
        "ground_truth": "Age <30: IDH1 (82.9%), TP53 (72.4%), ATRX (63.2%); Age 30-45: IDH1 (83.3%), TP53 (59.8%), ATRX (44.3%); Age 45-60: IDH1 (38.0%), TP53 (30.2%), ATRX (15.3%); Age >60: IDH1 (14.9%), TP53 (26.3%), ATRX (8.0%)",
        "derivation": "Mutation frequencies calculated by age group using groupBy and frequency counts",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Age <30: IDH1 (82.9%), TP53 (72.4%), ATRX (63.2%)\nAge 30-45: IDH1 (83.3%), TP53 (59.8%), ATRX (44.3%)\nAge 45-60: IDH1 (38.0%), TP53 (30.2%), ATRX (15.3%)\nAge >60: IDH1 (14.9%), TP53 (26.3%), ATRX (8.0%)\n\nThis shows the mutation frequencies for each gene across different age groups. There's a clear pattern where mutation frequencies for all three genes tend to be highest in younger patients (under 45 years) and decrease with age. IDH1 and ATRX mutations show particularly dramatic decreases in older age groups, while TP53 mutations show a more gradual decline.",
        "score": 1
    },
    {
        "question": "Compare the mean age at diagnosis between IDH1 mutated and wild-type patients. Express as 'IDH1-mutated: XX.XX years, IDH1-wildtype: YY.YY years', rounded to 2 decimal places.",
        "ground_truth": "IDH1-mutated: 41.67 years, IDH1-wildtype: 60.00 years",
        "derivation": "Analysis of age distributions and confidence intervals by mutation status",
        "type": "Information Retrieval",
        "subtype": "Contextual Interpretation and Explanation",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutated: 41.67 years, IDH1-wildtype: 59.54 years",
        "score": 1
    },
    {
        "question": "Calculate mutation frequencies by gender. Express as percentages rounded to 1 decimal place in format 'Gender X: IDH1 (XX.X%), TP53 (YY.Y%), ATRX (ZZ.Z%)'.",
        "ground_truth": "Gender 0: IDH1 (46.1%), TP53 (41.4%), ATRX (23.8%); Gender 1: IDH1 (51.0%), TP53 (41.6%), ATRX (28.8%)",
        "derivation": "Analyzed gender-specific mutation rates using data grouping and frequency calculations",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Gender 0: IDH1 (46.1%), TP53 (41.4%), ATRX (23.8%)\nGender 1: IDH1 (51.0%), TP53 (41.6%), ATRX (28.8%)",
        "score": 1
    },
    {
        "question": "Group patients into risk profiles based on mutation combinations. Report counts and mean ages in format 'RISK_LEVEL (COUNT patients, mean age XX.XX)'.",
        "ground_truth": "Low risk (404 patients, mean age 41.64), High risk (203 patients, mean age 60.89), Mixed (12 patients, mean age 41.39), No risk mutations (220 patients, mean age 59.35)",
        "derivation": "Created risk profiles based on combinations of high-risk (EGFR, PTEN) and low-risk (IDH1, CIC) mutations",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The patients can be grouped into four risk profiles:\n1. High Risk (181 patients, mean age 60.44) - characterized by EGFR mutations or multiple high-risk mutations\n2. Intermediate Risk (238 patients, mean age 38.78) - characterized by combined IDH1 and TP53 mutations\n3. Low Risk (165 patients, mean age 45.87) - characterized by IDH1 mutation alone\n4. Standard Risk (255 patients, mean age 58.82) - all other mutation combinations\n\nNotably, Intermediate Risk patients tend to be younger (mean age 38.78), while High Risk patients tend to be older (mean age 60.44). The analysis accounts for all 839 patients in the dataset.",
        "score": 0
    },
    {
        "question": "Calculate mutation frequencies by race. Express as 'Race X (n=N): IDH1 XX.X%, TP53 YY.Y%, ATRX ZZ.Z%'.",
        "ground_truth": "Race 0 (n=765): IDH1 49.8%, TP53 42.7%, ATRX 26.3%; Race 1 (n=59): IDH1 25.4%, TP53 30.5%, ATRX 22.0%; Race 2 (n=14): IDH1 57.1%, TP53 21.4%, ATRX 21.4%",
        "derivation": "Calculated mutation rates by racial groups using groupBy and frequency analysis",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Race 0 (n=765): IDH1 49.8%, TP53 42.7%, ATRX 26.3%\nRace 1 (n=59): IDH1 25.4%, TP53 30.5%, ATRX 22.0%\nRace 2 (n=14): IDH1 57.1%, TP53 21.4%, ATRX 21.4%\nRace 3 (n=1): IDH1 0.0%, TP53 0.0%, ATRX 0.0%\n\nThe results show the mutation frequencies for each race group, with Race 0 having the largest sample size (n=765) and showing relatively high mutation rates across all three genes. Race 1 (n=59) shows lower mutation frequencies compared to Race 0, while Race 2 (n=14) shows the highest IDH1 mutation rate but lower TP53 and ATRX rates. Race 3 has only one patient (n=1) with no mutations in any of these genes.",
        "score": 1
    },
    {
        "question": "Count patients by total number of mutations. Express as 'X mutations: N patients' for each group.",
        "ground_truth": "0 mutations: 124 patients, 1 mutation: 213 patients, 2 mutations: 262 patients, 3 mutations: 201 patients, 4 mutations: 35 patients, 5-7 mutations: 4 patients",
        "derivation": "Counted total number of mutations per patient and created frequency distribution",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Here's the distribution of patients by their total number of mutations:\n0 mutations: 67 patients\n1 mutations: 176 patients\n2 mutations: 224 patients\n3 mutations: 252 patients\n4 mutations: 93 patients\n5 mutations: 20 patients\n6 mutations: 3 patients\n9 mutations: 1 patient\n13 mutations: 1 patient\n17 mutations: 2 patients\n\nThis shows that most patients have between 1-4 mutations, with 3 mutations being the most common (252 patients). Very few patients have more than 6 mutations, with only a handful of cases showing 9 or more mutations.",
        "score": 0
    },
    {
        "question": "Calculate IDH1 mutation frequency by glioma grade. Express as 'Grade X: N/M (XX.X%)'.",
        "ground_truth": "Grade 0: 381/487 (78.2%), Grade 1: 23/352 (6.5%)",
        "derivation": "_.groupBy(data, 'Grade'); _.mapValues(groups, g => _.countBy(g, 'IDH1'))",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Grade 0: 381/487 (78.2%)\nGrade 1: 23/352 (6.5%)\n\nThis shows that IDH1 mutations are much more frequent in Grade 0 gliomas (78.2%) compared to Grade 1 gliomas (6.5%).",
        "score": 1
    },
    {
        "question": "Calculate mean age for IDH1-mutant vs wildtype patients. Express as 'IDH1-mutant: XX.X years, IDH1-wildtype: YY.Y years'.",
        "ground_truth": "IDH1-mutant: 41.7 years, IDH1-wildtype: 59.5 years",
        "derivation": "_.groupBy(data, 'IDH1'); calculate mean age for each group",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutant: 41.7 years, IDH1-wildtype: 59.5 years",
        "score": 1
    },
    {
        "question": "Calculate TP53 mutation rates in IDH1-mutant vs wildtype cases. Express as 'IDH1-mutant: N/M (XX.X%), IDH1-wildtype: P/Q (YY.Y%)'.",
        "ground_truth": "IDH1-mutant: 238/404 (58.9%), IDH1-wildtype: 110/435 (25.3%)",
        "derivation": "_.countBy(data, row => `IDH1:${row.IDH1},TP53:${row.TP53}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutant: 238/404 (58.9%), IDH1-wildtype: 110/435 (25.3%)\n\nThis shows that TP53 mutations are more common in IDH1-mutant cases (58.9%) compared to IDH1-wildtype cases (25.3%). The raw numbers show that 238 out of 404 IDH1-mutant cases have TP53 mutations, while 110 out of 435 IDH1-wildtype cases have TP53 mutations.",
        "score": 1
    },
    {
        "question": "Count total patients by gender. Express as 'N females (XX.X%), M males (YY.Y%)', percentages rounded to 1 decimal place.",
        "ground_truth": "488 females (58.2%), 351 males (41.8%)",
        "derivation": "_.countBy(data, 'Gender')",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "351 females (41.8%), 488 males (58.2%)",
        "score": 0
    },
    {
        "question": "Calculate IDH1 mutation frequency in Grade 0 gliomas. Express as 'N/M (XX.X%)'.",
        "ground_truth": "381/487 (78.2%)",
        "derivation": "filterByGrade(data, 0).filter(row => row.IDH1 === 1).length / filterByGrade(data, 0).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1 mutation frequency in Grade 0 gliomas is 381/487 (78.2%)",
        "score": 1
    },
    {
        "question": "Calculate the co-occurrence rate of EGFR and IDH1 mutations. Express as 'N/M (XX.X%) of EGFR-mutant cases have IDH1 mutations'.",
        "ground_truth": "4/112 (3.6%) of EGFR-mutant cases have IDH1 mutations",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "1/37 (2.7%) of EGFR-mutant cases have IDH1 mutations",
        "score": 0
    },
    {
        "question": "Compare mean age between IDH1-mutant and wildtype patients. Express as 'IDH1-mutant: XX.X years, IDH1-wildtype: YY.Y years'.",
        "ground_truth": "IDH1-mutant: 41.7 years, IDH1-wildtype: 59.5 years",
        "derivation": "compare mean age between IDH1-mutant and wildtype groups",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutant: 41.7 years, IDH1-wildtype: 59.5 years",
        "score": 1
    },
    {
        "question": "Calculate the frequency of ATRX mutations in IDH1-mutant cases. Express as 'N/M (XX.X%) of ATRX-mutant cases occur in IDH1-mutant gliomas'.",
        "ground_truth": "189/217 (87.1%) of ATRX-mutant cases occur in IDH1-mutant gliomas",
        "derivation": "_.countBy(data, row => `ATRX:${row.ATRX},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "188/404 (46.5%) of ATRX-mutant cases occur in IDH1-mutant gliomas",
        "score": 0
    },
    {
        "question": "Calculate concurrent mutation rates in PI3K pathway genes (PIK3CA, PIK3R1, PTEN). Express as 'Concurrent PIK3CA/PIK3R1: N cases (XX.X%), No mutations: M cases (YY.Y%)'.",
        "ground_truth": "Concurrent PIK3CA/PIK3R1: 3 cases (0.36%), No mutations: 591 cases (70.4%)",
        "derivation": "_.countBy(data, row => `PIK3CA:${row.PIK3CA},PIK3R1:${row.PIK3R1},PTEN:${row.PTEN}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Concurrent PIK3CA/PIK3R1: 3 cases (0.4%), No mutations: 591 cases (70.4%)\n\nThis shows that:\n1. Only 3 cases (0.4%) had concurrent mutations in both PIK3CA and PIK3R1\n2. The majority of cases (591 cases, 70.4%) had no mutations in any of the three PI3K pathway genes (PIK3CA, PIK3R1, and PTEN)",
        "score": 1
    },
    {
        "question": "Calculate the co-occurrence rate of PTEN and PIK3CA mutations. Express as 'N/M (XX.X%) of PTEN-mutant cases have PIK3CA mutations'.",
        "ground_truth": "7/141 (5.0%) of PTEN-mutant cases have PIK3CA mutations",
        "derivation": "_.countBy(data.filter(row => row.PTEN === 1), 'PIK3CA')",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "7/141 (5.0%) of PTEN-mutant cases have PIK3CA mutations",
        "score": 1
    },
    {
        "question": "Calculate IDH1 mutation frequency by race. Express as 'Race X: XX.X%' for each group.",
        "ground_truth": "Race 0: 49.8%, Race 1: 25.4%, Race 2: 57.1%",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Race 0: 49.8%\nRace 1: 25.4%\nRace 2: 57.1%\nRace 3: 0.0%\n\nThis shows that:\n- Race 2 has the highest IDH1 mutation frequency at 57.1%\n- Race 0 has the second highest at 49.8%\n- Race 1 has a lower frequency at 25.4%\n- Race 3 has no IDH1 mutations (0.0%)",
        "score": 1
    },
    {
        "question": "Is there a difference in EGFR mutation frequency across racial groups (yes / no). If so, express as 'Race X: XX.X%' for each group.",
        "ground_truth": "Yes.Race 0: 12.8%, Race 1: 22.0%, Race 2: 7.1%",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there are differences in EGFR mutation frequency across racial groups. Race 1: 22.0%, Race 0: 12.8%, Race 2: 7.1%, Race 3: 0.0%. However, it's important to note that some groups have very small sample sizes (particularly Race 3 with only 1 case), which may affect the reliability of these percentages.",
        "score": 1
    },
    {
        "question": "Calculate the co-occurrence rate of EGFR and PDGFRA mutations. Express as 'N/M (XX.X%) EGFR-mutant cases have PDGFRA mutations, P cases (YY.Y%) have neither'.",
        "ground_truth": "5/112 (4.5%) EGFR-mutant cases have PDGFRA mutations, 710 cases (84.6%) have neither",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},PDGFRA:${row.PDGFRA}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "5/112 (4.5%) EGFR-mutant cases have PDGFRA mutations, 710 cases (84.5%) have neither.\n\nThe calculation shows that out of all patients with EGFR mutations, only 5 also have PDGFRA mutations, while 710 patients have neither mutation. This suggests that co-occurrence of these mutations is relatively rare, occurring in less than 5% of EGFR-mutant cases.",
        "score": 1
    },
    {
        "question": "Calculate PDGFRA mutation associations with EGFR and IDH1 status. Express as 'N/M (XX.X%) in EGFR-wildtype, P/Q (YY.Y%) in IDH1-wildtype'.",
        "ground_truth": "17/22 (77.3%) in EGFR-wildtype, 16/22 (72.7%) in IDH1-wildtype",
        "derivation": "analysis of PDGFRA mutants with EGFR and IDH1 status",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "17/727 (2.3%) in EGFR-wildtype, 19/435 (4.4%) in IDH1-wildtype",
        "score": 0
    },
    {
        "question": "Analyze IDH1-ATRX-TP53 triple-positive cases. Express as 'N cases (XX.X%), mean age YY.Y years, Grade 0: ZZ.Z%'.",
        "ground_truth": "171 cases (20.4%), mean age 38.5 years, Grade 0: 90.1%",
        "derivation": "Analysis of co-occurrence patterns and clinical features in triple-positive cases",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "171 cases (20.4%), mean age 38.5 years, Grade 0: 90.1%",
        "score": 1
    },
    {
        "question": "How do alterations in the RTK/PI3K pathway members (EGFR, PDGFRA, PIK3CA, PIK3R1, PTEN) cooperate to drive gliomagenesis? Analyze whether they define specific molecular subtypes by calculating mutation frequencies in the RTK/PI3K pathway.Express as 'They have [similar / different] mechanisms of pathway activation. GENEX [is / is not] mutually exclusive with GENEY, GENEZ [has significant, has limited] co-ocurance with GENEA.",
        "ground_truth": "Yes, they have  different mechanisms for pathway activation. EGFR is mutually exclusive with PDGFRA, PIK3CA/PIK3R1 has limited co-occurrence with PTEN.",
        "derivation": "Complex pathway analysis including mutual exclusivity and co-occurrence patterns",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "They have different mechanisms of pathway activation. PTEN has the highest mutation frequency (16.81%), followed by EGFR (13.35%), PIK3CA (8.70%), PIK3R1 (6.44%), and PDGFRA (2.62%). EGFR is not mutually exclusive with PTEN, and they actually show a positive correlation (0.18), suggesting some co-occurrence. PIK3CA has limited co-occurrence with both EGFR and PTEN (correlation coefficients of 0.053 and -0.060 respectively). PDGFRA has very limited co-occurrence with other pathway members, showing near-zero correlations with PIK3CA (0.002) and PTEN (-0.014). PIK3R1 also shows limited co-occurrence with other pathway members, with correlation coefficients ranging from -0.029 to 0.048. This pattern suggests that these genes likely contribute to gliomagenesis through complementary but somewhat distinct mechanisms, with PTEN and EGFR alterations being the most prevalent.",
        "score": 0
    },
    {
        "question": "Do the distinct molecular profiles in different age groups suggest different cellular origins or evolutionary paths in glioma development (yes / no)? If yes, identify distinct molecular profile and averate age. Express as 'GENEX-GENEY-GENEZ: average age ZZ.Z, GENEA-GENEB: average age WW.W'",
        "ground_truth": "Yes. IDH1-ATRX-TP53: average age 38.5, EGFR-PTEN: average age 60.7",
        "derivation": "Integration of age patterns with molecular subtypes",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, IDH1-TP53-ATRX: average age 38.5, IDH1: average age 46.4\n\nThe data shows clear age-associated molecular profiles, with the triple-positive IDH1-TP53-ATRX mutation pattern occurring in younger patients (average age 38.5 years), while single IDH1 mutations are associated with older patients (average age 46.4 years). This suggests different cellular origins or evolutionary paths in glioma development, as the molecular profiles are distinctly age-dependent.\n\nThe most striking difference is between the triple-mutation pattern (IDH1-TP53-ATRX) occurring in younger patients versus single mutations occurring in older patients, suggesting that the pathways of glioma development may be age-dependent.",
        "score": 0
    },
    {
        "question": "How do chromatin modifiers (ATRX, SMARCA4, BCOR) interplay with metabolic alterations (IDH1)? Express as 'ChromatinModifierX: [frequent co-occurance (include %) / rare co-occurance]' for each chromatin modifier.",
        "ground_truth": "ATRX:frequent co-occurance (87.1%), SMARCA4 rare co-occurance, BCOR rare co-occurance.",
        "derivation": "Analysis of chromatin modifier co-occurrence patterns and associations",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "ATRX: frequent co-occurrence (46.5%) - This shows a strong association between ATRX and IDH1 mutations\nSMARCA4: rare co-occurrence (5.0%) - Very low co-occurrence with IDH1 mutations\nBCOR: rare co-occurrence (3.5%) - Very low co-occurrence with IDH1 mutations\n\nThe analysis reveals that among chromatin modifiers, ATRX has a strong interplay with IDH1 metabolic alterations, co-occurring in nearly half of IDH1-mutated cases. In contrast, both SMARCA4 and BCOR show rare co-occurrence with IDH1 mutations, suggesting limited direct interplay between these chromatin modifiers and IDH1-mediated metabolic alterations.",
        "score": 0
    },
    {
        "question": "Calculate distribution of molecular subtypes. Express as 'SUBTYPE: XX.X%, mean age YY.Y years' for each subtype.",
        "ground_truth": "IDH-triple: 20.4%, mean age 38.5 years; IDH-only: 19.8%, mean age 45.8 years; RTK/PI3K: 24.8%, mean age 60.3 years; Other: 35.0%, mean age 54.4 years",
        "derivation": "Integration of molecular subtypes with clinical characteristics",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutant: 48.2%, mean age 41.7 years\nIDH1-wildtype: 51.8%, mean age 59.5 years\n\nThis shows a relatively even distribution between IDH1-mutant and wildtype cases, with IDH1-mutant cases occurring in significantly younger patients (mean age 41.7 years) compared to IDH1-wildtype cases (mean age 59.5 years).\n\nNote: While there might be other molecular markers that could define additional subtypes (such as IDH2, TP53, etc.), IDH1 mutation status is one of the most important molecular markers in glioma classification. The data shows a clear age-dependent pattern that aligns with known clinical observations where IDH1-mutant gliomas tend to occur in younger patients.",
        "score": 0
    },
    {
        "question": "Calculate mutation frequencies by age group. Express as 'Age <45: IDH XX.X%, Age >60: RTK/PI3K YY.Y%'.",
        "ground_truth": "Age <45: IDH 83.3%, Age >60: RTK/PI3K 47.2%",
        "derivation": "Analysis of age-stratified molecular patterns and risk factors",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Age <45: IDH 87.9%, Age >60: RTK/PI3K 58.8%",
        "score": 0
    },
    {
        "question": "Calculate mean mutation burden by molecular subtype. Express as 'SUBTYPE: XX.X mutations (mean)'.",
        "ground_truth": "IDH-triple: 3.2 mutations (mean), RTK/PI3K: 1.8 mutations (mean)",
        "derivation": "Integration of mutation burden, pathway analysis, and clinical correlations",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "SUBTYPE 0: 2.6 mutations (mean)\nSUBTYPE 1: 1.8 mutations (mean)\n\nThis shows that:\n- Molecular subtype 0 has an average of 2.6 mutations per case\n- Molecular subtype 1 has an average of 1.8 mutations per case\n\nThe results indicate that subtype 0 tumors tend to have a higher mutation burden compared to subtype 1 tumors.",
        "score": 0
    },
    {
        "question": "Characterize molecular subtypes by age and prognosis. Express as 'SUBTYPE: onset age XX-YY years, PROGNOSIS' for each subtype.",
        "ground_truth": "IDH-triple: onset age 30-45 years, good prognosis; RTK/PI3K: onset age 55-70 years, poor prognosis",
        "derivation": "Analysis of subtype-specific characteristics and outcomes",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "IDH1-mutant with TP53/ATRX mutations: onset age 19-44 years, FAVORABLE PROGNOSIS\n- Typically younger patients (mean ~38 years)\n- Triple-positive (IDH1+/TP53+/ATRX+) represents classic lower-grade astrocytoma\n- Better prognosis due to IDH1 mutation\n\nIDH1-mutant without TP53/ATRX mutations: onset age 37-55 years, FAVORABLE PROGNOSIS\n- Intermediate age group (mean ~46 years)\n- Likely represents oligodendroglioma subtype\n- Generally favorable prognosis due to IDH1 mutation\n\nIDH1-wildtype: onset age 52-69 years, POOR PROGNOSIS\n- Older patients (mean ~60 years)\n- Molecular profile similar to primary glioblastoma\n- Poor prognosis due to aggressive nature and lack of IDH1 mutation\n\nThe rare subtype of IDH1-wildtype with TP53/ATRX mutations shows younger onset (mean ~40 years) but still carries POOR PROGNOSIS due to IDH1-wildtype status.",
        "score": 0
    }
]